Choreo LLC Acquires 220 Shares of Natera, Inc. (NASDAQ:NTRA)

Choreo LLC raised its position in shares of Natera, Inc. (NASDAQ:NTRA) by 12.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,986 shares of the medical research company’s stock after acquiring an additional 220 shares during the period. Choreo LLC’s holdings in Natera were worth $315,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Chartwell Investment Partners LLC increased its position in Natera by 37.9% during the third quarter. Chartwell Investment Partners LLC now owns 41,302 shares of the medical research company’s stock valued at $5,243,000 after acquiring an additional 11,362 shares during the last quarter. Cerity Partners LLC increased its position in Natera by 27.0% during the third quarter. Cerity Partners LLC now owns 86,144 shares of the medical research company’s stock valued at $10,936,000 after acquiring an additional 18,316 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new position in Natera during the third quarter valued at $385,000. Everence Capital Management Inc. bought a new position in Natera during the fourth quarter valued at $573,000. Finally, First Turn Management LLC bought a new position in Natera during the third quarter valued at $19,760,000. Institutional investors own 99.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on NTRA. Morgan Stanley boosted their price objective on shares of Natera from $132.00 to $176.00 and gave the company an “overweight” rating in a research report on Thursday, November 14th. TD Cowen raised their price target on shares of Natera from $155.00 to $175.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Piper Sandler raised their price target on shares of Natera from $150.00 to $200.00 and gave the stock an “overweight” rating in a research note on Monday, November 18th. Canaccord Genuity Group raised their price target on shares of Natera from $165.00 to $180.00 and gave the stock a “buy” rating in a research note on Friday, January 3rd. Finally, Barclays initiated coverage on shares of Natera in a research note on Thursday, January 23rd. They issued an “overweight” rating and a $200.00 price target on the stock. One equities research analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $165.88.

Natera Stock Down 0.7 %

NASDAQ:NTRA opened at $170.73 on Friday. Natera, Inc. has a fifty-two week low of $68.03 and a fifty-two week high of $183.00. The stock has a market capitalization of $22.54 billion, a P/E ratio of -97.01 and a beta of 1.66. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. The company’s 50-day simple moving average is $167.68 and its 200-day simple moving average is $142.15.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.31. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The business had revenue of $439.80 million for the quarter, compared to analysts’ expectations of $361.43 million. During the same period last year, the business earned ($0.95) EPS. The company’s revenue was up 63.9% compared to the same quarter last year. On average, equities analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Roelof Botha sold 87,473 shares of Natera stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $169.12, for a total value of $14,793,433.76. Following the completion of the sale, the director now directly owns 1,224,787 shares in the company, valued at $207,135,977.44. This trade represents a 6.67 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Steven Leonard Chapman sold 78,553 shares of Natera stock in a transaction that occurred on Wednesday, January 22nd. The stock was sold at an average price of $164.97, for a total transaction of $12,958,888.41. Following the completion of the sale, the chief executive officer now owns 267,629 shares of the company’s stock, valued at $44,150,756.13. This trade represents a 22.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 305,454 shares of company stock worth $51,290,625. Corporate insiders own 7.60% of the company’s stock.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.